Which biologic best stops Crohn's from coming back after surgery?

NCT ID NCT07694674

Recruiting now Disease control Sponsor: Shanghai 10th People's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at whether certain biologic drugs (like infliximab, adalimumab, vedolizumab, and ustekinumab) can prevent Crohn's disease from flaring up again after bowel surgery. Researchers will review medical records of about 198 adults who started one of these drugs within six weeks after surgery. The main goal is to see which drug is best at keeping the disease in remission, based on follow-up colonoscopy results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Biologic agents (infliximab, adalimumab, vedolizumab, ustekinumab)
What this could lead to: If one biologic proves more effective, it could help doctors choose the best drug to prevent Crohn's disease from returning after surgery.
What could go wrong: This is a retrospective study, not a controlled trial, so results may be less reliable. The drugs may not prevent recurrence in all patients and carry risks like infection or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD) INFLAMATORY BOWEL DISEASE

Contacts and locations

Show contact details

Locations

The Tenth People's Hospital of Shanghai
RECRUITING

Shanghai, Shanghai Municipality, 201505, China

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.